Pharmacy Times October 18, 2024
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, Amir Ali, PharmD, BCOP, Brooke Adams, PharmD, BCOP

Key Takeaways

  • New therapies must show significant clinical improvements, such as enhanced efficacy or reduced side effects, over current standards to be considered for adoption.
  • Cost-effectiveness, ease of administration, and alignment with existing protocols are crucial non-clinical factors influencing treatment adoption decisions.
  • The impact on healthcare resources, infrastructure, and acceptance by patients and providers are critical considerations in evaluating new therapies.

Panelists discuss how a new therapy for multiple myeloma would need to demonstrate significant improvements in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
Related Articles:
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article